Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several statements (e.g., with/without food dosing, general need to report muscle symptoms, and liver-related evaluation language) align with the label excerpts, but multiple details are not supported by the provided label text—especially claims about food’s effect on absorption/tolerability and the specificity of symptom examples.
Category Scores
Accurate Statements
Lipitor (atorvastatin) can be taken with or without food.
Label Section 2.1: “LIPITOR can be administered as a single dose at any time of the day, with or without food…”
Lipitor should be taken consistently at about the same time each day.
Label Section 2.1: “once daily” (supports consistent daily timing; label text provided does not explicitly say “same time,” but the once-daily regimen is consistent with this instruction).
Muscle pain, weakness, or dark urine associated with Lipitor should be reported promptly to a clinician.
Label Section 5.1: warnings about myopathy/rhabdomyolysis and “temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy.” (Label excerpt does not explicitly include “dark urine,” nor the exact “promptly report” phrasing.)
Seek medical advice if severe or persistent muscle pain or weakness develops.
Label Section 5.1: “Rare cases of rhabdomyolysis…” and “LIPITOR therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy…” (supports the need for medical attention; exact “severe or persistent” wording not in excerpt).
Seek medical advice if signs of liver problems develop during Lipitor therapy (e.g., unusual fatigue, dark urine, yellowing of eyes/skin).
Label Section 5.2 discusses liver dysfunction monitoring and contraindication for active liver disease; however the provided excerpts do not list these specific symptom examples.
Seek medical advice if allergic symptoms such as swelling or rash develop.
Label Section 6.2: postmarketing adverse reactions include “anaphylaxis, angioneurotic edema…” (supports allergy-related medical advice; provided excerpt does not explicitly mention “rash”).
Unsupported Statements
Taking Lipitor with food does not generally change how the drug works.
No label excerpt provided states that food does not change drug action/effect.
Taking Lipitor with food can help some people tolerate it if food makes stomach upset less likely.
No label excerpt provided addresses tolerability improvement with food or stomach upset reduction.
Food may slow the timing of Lipitor absorption.
No label excerpt provided discusses absorption timing with respect to food.
Food does not prevent Lipitor from being absorbed.
No label excerpt provided discusses whether food prevents absorption.
Lipitor can fit into a meal routine.
No label excerpt provides this behavioral guidance beyond dosing being “with or without food.”
Food mainly helps with stomach discomfort rather than muscle side effects.
No label excerpt provided links food to gastrointestinal vs muscle side-effect differences.
If gastrointestinal discomfort occurs with Lipitor, taking it with a meal is a common approach.
No label excerpt provided recommends taking Lipitor with meals to address GI discomfort.
Seek medical advice if signs of liver problems develop during Lipitor therapy (e.g., unusual fatigue, dark urine, yellowing of eyes/skin).
The provided label excerpts discuss monitoring and contraindications but do not include these specific symptom examples.
Contradictions
Important Omissions
Any statement about contraindications (e.g., pregnancy) and/or boxed warnings (if applicable) is omitted from the provided claims.
Importance:
Moderate
Liver monitoring recommendation (e.g., liver function tests prior to and at 12 weeks following initiation and periodically thereafter) is not mentioned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Core dosing with/without food is supported, but several GI/absorption/tolerability assertions are unsupported by the supplied excerpts. Additionally, liver-related symptom examples and the instruction to report muscle symptoms lack explicit label support in the provided text, which could lead to overconfidence in specific symptom framing.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple food-related mechanistic/tolerability statements (absorption timing, tolerability improvement, and specific symptom-based guidance) are not supported by the provided label excerpts.
Suggested Improvement
Limit food-related claims to what the label excerpt supports (administration “with or without food” and “once daily at any time of day”). For safety counseling, align to the label language provided (e.g., myopathy/rhabdomyolysis warnings and liver function test/contraindication language) without adding symptom examples not present in the supplied excerpts.